Lytix Biopharma AS has decided to initiate the process to secure funding of the company’s development program, including phase II clinical trials in the US for the lead candidate LTX-315. The board of directors has mandated the management to subsequently list its shares on Euronext Growht Oslo. Arctic Securities and Sparebank 1 Markets have been engaged as financial advisors in the process.
“Cancer is one of the world’s largest health problems and our goal is that Lytix Biopharma's technology will play an important role in cancer treatment in the future. We develop medicines across several cancer indications based on immunotherapy, activating the body's own immune system to recognize and kill a variety of cancer cells. LTX-315 has shown very promising efficacy and safety signals and we are excited to enter the next chapter of the company’s history,” says Øystein Rekdal, CEO of Lytix Biopharma.